1. To evaluate the role of VerifyNow test as prognostic marker in routine clinical practice using drug-eluting stents. 2. To determine the add-on-effect of VerifyNow test beyond on conventional risk factors (clinical, lesions, or procedural factors). 3. To compare the prognostic utility of VerifyNow test with several biomarkers.
Predictive role of a point-of-care assay (VerifyNow test) has not been well evaluated in large number of patients receiving drug-eluting stents as a routine practice. In addition, additional predictive effect of a point-of-care assay, as compared to conventional clinical factors or other biomarkers, might be clinically interesting and important.
Study Type
OBSERVATIONAL
Enrollment
3,000
Asan Medical Center
Seoul, South Korea
Composite of all-cause death, myocardial infarction, stent thrombosis, and stroke
Time frame: at median 2 year after enrollment
death (all-cause and cardiovascular)
Time frame: at median 2 year after enrollment
myocardial infarction
Time frame: at median 2 year after enrollment
stent thrombosis
Time frame: at median 2 year after enrollment
stroke
Time frame: at median 2 year after enrollment
Thrombolysis In Myocardial Infarction (TIMI) major/minor bleeding
Time frame: at median 2 year after enrollment
target-vessel revascularization
Time frame: at median 2 year after enrollment
Composite of cardiovascular death, MI, stent thrombosis, or stroke
Time frame: at median 2 year after enrollment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.